Regeneron Pharmaceuticals (REGN) Change in Cash (2009 - 2026)

Regeneron Pharmaceuticals' Change in Cash history runs 18 years deep, the most recent figure standing at -$153.1 million for Q1 2026.

• On a quarterly basis, Change in Cash fell 125.35% year-over-year to -$153.1 million in Q1 2026; TTM through Mar 2026 was -$122.4 million, a 125.33% decrease from a year earlier, with the FY2025 full-year figure at $634.7 million, up 355.1% from the prior year.
• Change in Cash fell to -$153.1 million in Q1 2026 per REGN's latest filing, from $610.6 million in the prior quarter.
• Across five years, Change in Cash topped out at $809.4 million in Q1 2023 and bottomed at -$2.0 billion in Q2 2023.
• The 5-year median for Change in Cash is $96.2 million (2022), against an average of $4.3 million.
• Across the five-year window, Change in Cash sank 4106.28% in 2023 and jumped 571.88% in 2025, its largest moves.
• Year by year, Change in Cash stood at -$385.4 million in 2022, then jumped by 249.87% to $577.6 million in 2023, then declined by 17.38% to $477.2 million in 2024, then gained by 27.95% to $610.6 million in 2025, then plunged by 125.07% to -$153.1 million in 2026.
• Per Business Quant, the three latest REGN Change in Cash figures stand at -$153.1 million (Q1 2026), $610.6 million (Q4 2025), and $497.5 million (Q3 2025).